期刊文献+

交叉抗药性药物创新性专利保护的两难选择

Dilemma of Patent Protection of the Innovative Drug with Cross-Resistance
下载PDF
导出
摘要 立法是对社会资源和利益的第一次分配,立法者通过各种制度设计分配社会资源和利益,引导社会资源向有利于社会整体效益最大化的方向流动。为了使公众在疾病谱不断变化的过程中能够及时得到有效治疗,就必须激励药物生产者不断研发创新,而为了激励药物创新就必须加强创新药物的专利保护,但是,有些受到专利保护的创新药物如抗菌药等,在使用过程中会对现在或未来某种新药产生交叉抗药性,从而使其失去药效,这显然对那些新药研发企业是不公平的,对社会总福利也是不利的。这是一个两难选择,走出这个困境,需要重新审视专利立法的价值取向,并在制度上进行再设计。 Legislation is the first allocation for social resource and interests. The legislators guide social resources to the benefit of the whole society through a variety of system to distribute the social resources and the interests. In order to let the public be effectively treated in a timely manner, it is necessary to encourage producers to continue to develop innovative drugs, and then we should strengthen the innovation of drug patent protection in order to encourage the drug innovation. However, some innovation drugs protected by patent including anti-bacterial drug can produce a cross-resistance to the same kind of drugs in the present or the future as to make them lose its efficacy, it is clear that it is unfair for those medicine company and the total social welfare. This is a dilemma, out of this predicament, we should re-examine the patent legislation of the values and institutional re-design.
出处 《昆明理工大学学报(社会科学版)》 2009年第8期49-52,共4页 Journal of Kunming University of Science and Technology(Social Sciences)
关键词 交叉抗药性 药物 创新性 专利保护 公正性 Cross-resistance drug innovative patent protection impartiality
  • 相关文献

参考文献11

  • 1诺内特·塞尔兹尼克.转变中的法律与社会[M].张志铭译.北京:中国政法大学出版社.1994.
  • 2谢玉英,李绪友.警惕细菌的抗药性[J].中国科技信息,2007(9):178-178. 被引量:3
  • 3中国卫生产业网[EB/OL].http/www.zgwscy.com/content.asp?id=3384.
  • 4p: //www. sciencedaily. com/releases/2004/09/ 040923093007. htm.
  • 5http: //www. southcentre, org/publications/trips/ tripsmaintexttrans- 04. htm (last visited May, 19, 2008).
  • 6Lewis, supra note 37 ; see also Union of Concerned Scientists, FDA "s Approach to Antibiotic Regulation - "The Framework Document".
  • 7Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in Biomedical Research 280 SCIENCE, 698,698 (May 1998) ; Implications of the TRIPs Agreement for Developing Countries.
  • 8Chirac, et al. , Access to Essential Medicines in Poor Countries: a Lost Battle?, 281 JAMA 362 (1999).
  • 9Rantardal and Dhirajlal, the Law of Tort 407 (Guru Prasana Singh ed. , 2006).
  • 10http: //www. fda. gov/Fdac/features1795 antibio. html (last visited May 19, 2008).

二级参考文献3

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部